Technical Analysis for CGEM - Cullinan Management, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | -2.70% | |
| Wide Bands | Range Expansion | -2.70% | |
| Below Lower BB | Weakness | -2.70% | |
| Down 3 Days in a Row | Weakness | -2.70% | |
| Down 4 Days in a Row | Weakness | -2.70% | |
| Down 5 Days in a Row | Weakness | -2.70% | |
| Lower Bollinger Band Touch | Weakness | -2.70% | |
| Oversold Stochastic | Weakness | -2.70% | |
| NR7 | Range Contraction | -6.56% | |
| Narrow Range Bar | Range Contraction | -6.56% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 25 minutes ago |
| Down 3% | 40 minutes ago |
| Fell Below Previous Day's Low | about 1 hour ago |
| Down 2 % | about 1 hour ago |
| Down 1% | about 1 hour ago |
Get a Trading Sidekick!
- Earnings date: 11/06/2024
Cullinan Management, Inc. Description
Cullinan Oncology, LLC, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Its lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. The company's preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell acute lymphoblastic leukemia; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. It has a collaboration agreement with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, LLC was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Solid Tumors Immune System Antibodies Oncology Tumor Cancer Immunotherapy Monoclonal Antibody Cell Therapy Acute Myeloid Leukemia Non Small Cell Lung Cancer Therapies For Cancer Treatment Of Acute Myeloid Leukemia Oncology Therapies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.1886 |
| 52 Week Low | 7.6818 |
| Average Volume | 541,844 |
| 200-Day Moving Average | 18.45 |
| 50-Day Moving Average | 16.24 |
| 20-Day Moving Average | 15.49 |
| 10-Day Moving Average | 14.90 |
| Average True Range | 1.02 |
| RSI (14) | 30.07 |
| ADX | 15.5 |
| +DI | 13.96 |
| -DI | 28.86 |
| Chandelier Exit (Long, 3 ATRs) | 14.46 |
| Chandelier Exit (Short, 3 ATRs) | 15.55 |
| Upper Bollinger Bands | 17.93 |
| Lower Bollinger Band | 13.05 |
| Percent B (%b) | -0.1 |
| BandWidth | 31.48 |
| MACD Line | -0.79 |
| MACD Signal Line | -0.44 |
| MACD Histogram | -0.3513 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.10 | ||||
| Resistance 3 (R3) | 14.25 | 13.88 | 13.85 | ||
| Resistance 2 (R2) | 13.88 | 13.49 | 13.81 | 13.76 | |
| Resistance 1 (R1) | 13.23 | 13.25 | 13.05 | 13.09 | 13.68 |
| Pivot Point | 12.87 | 12.87 | 12.77 | 12.79 | 12.87 |
| Support 1 (S1) | 12.22 | 12.48 | 12.03 | 12.07 | 11.48 |
| Support 2 (S2) | 11.85 | 12.24 | 11.78 | 11.40 | |
| Support 3 (S3) | 11.20 | 11.85 | 11.31 | ||
| Support 4 (S4) | 11.06 |
